Register Login

SAB Biotherapeutics (SABSW)

(30% Negative) SAB BIOTHERAPEUTICS, INC. (SABSW) Announces Delay in confidence Trials for advancing innov Due to Regulatory Process, Manufacturing Considerations

Full text
Register to leave comments
  • News bot Jan. 7, 2026, 1:32 p.m.

    📋 SAB BIOTHERAPEUTICS, INC. (SABSW) - Clinical Trial Update

    Filing Date: 2026-01-07

    Accepted: 2026-01-07 08:30:26

    Event Type: Clinical Trial Update

    Event Details:

    SAB Biotherapeutics (SABSW) Announces Clinical Trial Update SAB Biotherapeutics (SABSW) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: confidence, launches
    • Diseases/Conditions: advancing innov
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Regulatory Process
    • Collaboration: Board

    🔬 Clinical Development Pipeline (SAB BIOTHERAPEUTICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    JMT108 DRUG Phase PHASE1 Cancer ClinicalTrials.gov
    Pembrolizumab DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    DM919 DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    Placebo OTHER Phase PHASE2 Type 1 Diabetes ClinicalTrials.gov
    Low Dose SAB-142 DRUG Phase PHASE2 Type 1 Diabetes ClinicalTrials.gov
    High Dose SAB-142 DRUG Phase PHASE2 Type 1 Diabetes ClinicalTrials.gov
    A2B694 BIOLOGICAL Phase PHASE1 Solid Tumor, Adult ClinicalTrials.gov
    JK07 DRUG Phase PHASE2 HFrEF - Heart Failure With Reduced Ejection Fraction ClinicalTrials.gov
    AG-73305 BIOLOGICAL Phase PHASE2 Diabetic Macular Edema ClinicalTrials.gov
    VOY-101 BIOLOGICAL Phase PHASE1 Age-Related Macular Degeneration ClinicalTrials.gov
    Dose Level 4, VNX-202 GENETIC Phase PHASE1 HER2 Expressing Solid Tumors ClinicalTrials.gov
    Dose Level 3, VNX-202 GENETIC Phase PHASE1 HER2 Expressing Solid Tumors ClinicalTrials.gov
    Dose Level 2, VNX-202 GENETIC Phase PHASE1 HER2 Expressing Solid Tumors ClinicalTrials.gov
    Dose Level 1, VNX-202 GENETIC Phase PHASE1 HER2 Expressing Solid Tumors ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: SAB Biotherapeutics
    • CIK: 0001833214
    • Ticker Symbol: SABSW
    • Period End Date: 2026-01-05
    • Document Type: 8-K

Search

News categories